Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study.
Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study.
复制标题
DOI：
10.1186/1471-2407-12-542
复制
发表时间：
2012-11-22
期刊：
影响因子：
3.8
通讯作者：
Nemoto K
中科院分区：
文献类型：
--
作者：
Jingu K;Matsushita H;Takeda K;Umezawa R;Takahashi C;Sugawara T;Kubozono M;Abe K;Tanabe T;Shirata Y;Yamamoto T;Ishikawa Y;Nemoto K
2006年，我们报道了放化疗对术后复发食管癌的有效性，中位观察期为18个月。本研究的目的是更新放疗联合奈达铂和5-氟尿嘧啶（5-FU）治疗术后局部区域复发食管癌的结果。在2000年至2004年期间，我们进行了一项II期研究，采用放疗（60戈伊/30次/6周）联合化疗治疗术后局部区域复发性食管癌，化疗包括两个周期的奈达铂（70 mg/m2/2 h）和5-FU（500 mg/m2/24 h，持续5天）。主要终点为总生存率，次要终点为无进展生存率、射野控制率和慢性毒性。本研究共入组30例患者。76.7%的患者完成了方案。存活者的中位观察期为72.0个月。5年总生存率为27.0%，中位生存期为21.0个月。5年无进展生存率和照射野控制率分别为25.1%和71.5%。仅在1例患者中观察到3级或3级以上晚期毒性。两名长期生存者在放化疗后5年以上患上了胃管癌。治疗前体能状态、复发模式（吻合口复发患者更差）和复发病变数量（多发性复发病变患者更差）是总生存期的统计学显著预后因素。放疗联合奈达铂和5-FU是治疗食管癌术后局部复发的安全有效的挽救治疗方法。但多区域复发或吻合口复发的患者预后极差。
In 2006, we reported the effectiveness of chemoradiotherapy for postoperative recurrent esophageal cancer with a median observation period of 18 months. The purpose of the present study was to update the results of radiotherapy combined with nedaplatin and 5-fluorouracil (5-FU) for postoperative loco-regional recurrent esophageal cancer. Between 2000 and 2004, we performed a phase II study on treatment of postoperative loco-regional recurrent esophageal cancer with radiotherapy (60 Gy/30 fractions/6 weeks) combined with chemotherapy consisting of two cycles of nedaplatin (70 mg/m2/2 h) and 5-FU (500 mg/m2/24 h for 5 days). The primary endpoint was overall survival rate, and the secondary endpoints were progression-free survival rate, irradiated-field control rate and chronic toxicity. A total of 30 patients were enrolled in this study. The regimen was completed in 76.7% of the patients. The median observation period for survivors was 72.0 months. The 5-year overall survival rate was 27.0% with a median survival period of 21.0 months. The 5-year progression-free survival rate and irradiated-field control rate were 25.1% and 71.5%, respectively. Grade 3 or higher late toxicity was observed in only one patient. Two long-term survivors had gastric tube cancer more than 5 years after chemoradiotherapy. Pretreatment performance status, pattern of recurrence (worse for patients with anastomotic recurrence) and number of recurrent lesions (worse for patients with multiple recurrent lesions) were statistically significant prognostic factors for overall survival. Radiotherapy combined with nedaplatin and 5-FU is a safe and effective salvage treatment for postoperative loco-regional recurrent esophageal cancer. However, the prognosis of patients with multiple regional recurrence or anastomotic recurrence is very poor.
登录
查看更多内容
影响因子：
5.2
作者：
Sugiura, T;Kato, H;Nakanishi, Y
通讯作者：
Nakanishi, Y
影响因子：
9
作者：
FUJITA, H;KAKEGAWA, T;MIZUTANI, K
通讯作者：
MIZUTANI, K
DOI：
10.1007/bf02736700
发表时间：
2003-11-01
期刊：
The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi
影响因子：
--
作者：
Kato, Hiroyuki;Miyazaki, Tatsuya;Kuwano, Hiroyuki
通讯作者：
Kuwano, Hiroyuki
影响因子：
24.5
作者：
RAOUL, JL;LEPRISE, E;LAUNOIS, B
通讯作者：
LAUNOIS, B
影响因子：
2.4
作者：
Niibe Y;Hayakawa K
通讯作者：
Hayakawa K